Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

  1. Bertolotto, A.
  2. Arroyo, R.
  3. Celius, E.G.
  4. Comi, G.
  5. Havrdova, E.K.
  6. Honeycutt, W.D.
  7. Hunter, S.F.
  8. Izquierdo, G.
  9. Kornek, B.
  10. Miller, T.
  11. Mitsikostas, D.D.
  12. Singer, B.A.
  13. Ziemssen, T.
  14. Chung, L.
  15. Daizadeh, N.
  16. Afsar, S.
  17. Hashemi, L.
  18. Senior, P.
Journal:
Neurology and Therapy

ISSN: 2193-6536 2193-8253

Year of publication: 2020

Volume: 9

Issue: 2

Pages: 443-457

Type: Article

DOI: 10.1007/S40120-020-00191-7 GOOGLE SCHOLAR lock_openOpen access editor